Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report

BackgroundImmune checkpoint inhibitors targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed death-1 receptor (PD-1), and programmed death-1 receptor and its ligand (PD-L1) increased the survival of patients affected by metastatic malignant melanoma. Due to their mechanism of ac...

Full description

Bibliographic Details
Main Authors: Maria Anna Siciliano, Stefano Dastoli, Maria d’Apolito, Nicoletta Staropoli, Pierfrancesco Tassone, Pierosandro Tagliaferri, Vito Barbieri
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
immune-related adverse events
cutaneous immune-related adverse events
psoriasis
checkpoint inhibitors
immunotherapy
Pembrolizumab
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.579445/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.579445/full

Similar Items